A 5-Genomic Mutation Signature Can Predict the Survival for Patients With NSCLC Receiving Atezolizumab

BACKGROUND: At present, there is a lack of studies focusing on the survival prediction of patients with non-small cell lung cancer (NSCLC) receiving atezolizumab in light of gene mutation characteristic. METHODS: Patients with NSCLC receiving atezolizumab from the OAK study were defined as the train...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Autores principales: Lin, Jiamao, Wang, Xiaohui, Zhang, Chenyue, Bu, Shuai, Zhao, Chenglong, Wang, Haiyong
Formato: Artigo
Lenguaje:Inglês
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC8261129/
https://ncbi.nlm.nih.gov/pubmed/34248926
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.606027
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares